Invited Speaker 37th TROG Cancer Research Annual Scientific Meeting 2025

R2810-ONC-1788 |TROG 17.11 cPOST: A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous (#36)

Danny Rischin 1
  1. Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Content is not available at the time of publishing.